A few months ago Bert Vogelstein published an excellent analysis of the accumulated cancer genome sequencing data suggesting that we had identified basically all the cancer driver mutations (~140) that are likely to be found in most tumors. In essence, we have saturated the screen. However, now the Elledge lab suggests an alternative perspective, that a many more genes are involved in driving tumor formation but each in a graded manner. In either case, it seems clear that the age of new oncogene identification is drawing to a close. Next task: figuring out what many of these genes do and how they can be targetted to induce tumor-specific cell death.